Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms

被引:18
|
作者
Shimomura, Yutaro [1 ]
Kikuchi, Yuhei [1 ]
Suzuki, Takefumi [2 ]
Uchida, Hiroyuki [1 ]
Mimura, Masaru [1 ]
Takeuchi, Hiroyoshi [1 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[2] Univ Yamanashi, Fac Med, Dept Neuropsychiat, Yamanashi, Japan
关键词
Algorithms; Antipsychotics; Guidelines; Non-response; Schizophrenia; Treatment resistance; NAIVE 1ST-EPISODE SCHIZOPHRENIA; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED-TRIAL; CLOZAPINE; AUGMENTATION; METAANALYSIS; MANAGEMENT; DRUGS; SCALE; RISPERIDONE;
D O I
10.1016/j.schres.2021.07.040
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: To summarize the current state of knowledge on antipsychotic treatment strategies for the acute phase and treatment resistance in schizophrenia, we conducted a systematic review of guidelines and algorithms. Methods: We conducted a systematic literature search to identify clinical guidelines and algorithms on this topic using MEDLINE and Embase. We extracted information on recommendations for antipsychotic treatment strategies, including those for non-response (i.e., increasing antipsychotic dose and switching to another antipsychotic) and treatment resistance. Results: We identified a total of 17 guidelines/algorithms in various countries that were published after 2011. With respect to antipsychotic dose, most of the guidelines (N = 10/11) agreed starting with a low dose or the lowest licensed/effective dose and then titrating the dose upwards. Regarding antipsychotic treatment strategies for non-response, all of the guidelines (N = 9/9) recommended increasing antipsychotic dose towards the upper end of its approved dose range. Five guidelines suggested for increasing beyond the therapeutic dose range in exceptional cases, while overall 10 guidelines including them were negative about such strategy. The vast majority of guidelines (N = 16/17) recommended switching to another antipsychotic for non-response; however, some guidelines mentioned the lack of evidence for these strategies other than the use of clozapine. All the guidelines (N = 17/17) endorsed initiating clozapine after failure to respond to 2 different antipsychotics. Four guidelines endorsed an early use of clozapine, yet as the third antipsychotic. Conclusion: The currently available guidelines and algorithms recommended increasing antipsychotic dose and switching to another antipsychotic, particularly clozapine for treatment-resistant schizophrenia, during the acute phase of schizophrenia for non-response.
引用
收藏
页码:142 / 155
页数:14
相关论文
共 50 条
  • [41] Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia
    Sadowska-Bartosz, Izabela
    Galiniak, Sabina
    Bartosz, Grzegorz
    Zuberek, Mariusz
    Grzelak, Agnieszka
    Dietrich-Muszalska, Anna
    SCHIZOPHRENIA RESEARCH, 2016, 176 (2-3) : 245 - 251
  • [42] Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials
    Galling, Britta
    Roldan, Alexandra
    Rietschel, Liz
    Hagi, Katsuhiko
    Walyzada, Frozan
    Zheng, Wei
    Cao, Xiao-Lan
    Xiang, Yu-Tao
    Kane, John M.
    Correll, Christoph U.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) : 591 - 612
  • [43] Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance
    Wagner, Elias
    Loehrs, Lisa
    Siskind, Dan
    Honer, William G.
    Falkai, Peter
    Hasan, Alkomiet
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (04) : 423 - 435
  • [44] Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
    Amy L. Gillespie
    Ruta Samanaite
    Jonathan Mill
    Alice Egerton
    James H. MacCabe
    BMC Psychiatry, 17
  • [45] Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
    Gillespie, Amy L.
    Samanaite, Ruta
    Mill, Jonathan
    Egerton, Alice
    MacCabe, James H.
    BMC PSYCHIATRY, 2017, 17
  • [46] Medication management of antipsychotic treatment in schizophrenia-A narrative review
    Isohanni, Matti
    Jaaskelainen, Erika
    Miller, Brian J.
    Hulkko, Anja
    Tiihonen, Jari
    Moeller, Hans-Jurgen
    Hartikainen, Sirpa
    Huhtaniska, Sanna
    Lieslehto, Johannes
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2021, 36 (02)
  • [47] Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
    Coles, Alexandria S.
    Knezevic, Dunja
    George, Tony P.
    Correll, Christoph U.
    Kane, John M.
    Castle, David
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [48] Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis
    Okhuijsen-Pfeifer, C.
    Huijsman, E. A. H.
    Hasan, A.
    Sommer, I. E. C.
    Leucht, S.
    Kahn, R. S.
    Luykx, J. J.
    ACTA PSYCHIATRICA SCANDINAVICA, 2018, 138 (04) : 281 - 288
  • [49] Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis
    Krause, Marc
    Huhn, Maximilian
    Schneider-Thoma, Johannes
    Rothe, Philipp
    Smith, Robert C.
    Leucht, Stefan
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (12) : 1360 - 1370
  • [50] A Comprehensive Review of Schizophrenia and Antipsychotic Metabolism as a Predictor of Treatment Response
    Pham, Mia
    Caglayan, Aydin
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)